GlassScriptPhysician profile
Sramila Aithal
NPI 1205029816
$681,827.94
in general payments reported to CMS, 2019-2025
67 companies · $119K in 2025
The $119K reported for 2025 was more than what 98% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $56K · 2021: $77K · 2022: $86K · 2023: $151K · 2024: $141K · 2025: $119K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $314K · Consulting Fee: $61K · Travel and Lodging: $26K · Food and Beverage: $9,358 · Education: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $314,088.93 |
| Consulting Fee | $61,166.98 |
| Travel and Lodging | $26,172.47 |
| Food and Beverage | $9,358.04 |
| Education | $428.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $204,801.35 | 2019-2025 | |
| Gilead Sciences, INC. | $156,885.16 | 2019-2025 | Trodelvy |
| Seagen INC. | $72,787.49 | 2020-2023 | Tukysa, Adcetris |
| Lilly USA, LLC | $67,596.96 | 2020-2025 | Verzenio |
| Daiichi Sankyo INC. | $63,075.40 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $38,511.24 | 2019-2025 | Kisqali |
| Astrazeneca Pharmaceuticals LP | $32,531.20 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Puma Biotechnology, INC. | $14,946.50 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $13,655.87 | 2019-2025 | Lynparza, Keytruda, Welireg |
| Eli Lilly and Company | $5,689.00 | 2022-2025 | |
| Genzyme Corporation | $2,962.03 | 2021-2025 | |
| Fresenius Kabi USA, LLC | $2,570.00 | 2021-2022 | |
| Pfizer International LLC | $1,800.00 | 2020 | |
| Abbvie INC. | $469.40 | 2021-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $431.09 | 2019-2025 | Opdivo, Opdualag |
Show all 63 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sramila Aithal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.